(AXSM) Axsome Therapeutics - Ratings and Ratios

Axsome Therapeutics, Inc. is a biopharmaceutical company specializing in the development of innovative therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company has established a robust portfolio targeting significant unmet needs in neuroscience. Axsomes approach emphasizes multi-target drug development, aiming to address complex CNS conditions through a unique combination of mechanisms.

The companys commercial products include Auvelity (dextromethorphan-bupropion), Sunosi (solriamfetol), and Symbravo (AXS-07), each designed with distinct pharmacological profiles. Auvelity, an NMDA receptor antagonist and sigma-1 receptor agonist, is approved for major depressive disorder. Sunosi, a dopamine and norepinephrine reuptake inhibitor, treats excessive daytime sleepiness in narcolepsy and sleep apnea. Symbravo, a COX-2 inhibitor and 5-HT1B/1D agonist, offers acute migraine treatment.

Axsomes pipeline includes AXS-05, AXS-12, AXS-14, and Solriamfetol, each in advanced clinical trials for conditions like Alzheimers agitation, narcolepsy, fibromyalgia, and ADHD. A collaboration with Duke University evaluates AXS-05 for smoking cessation, highlighting their commitment to addressing diverse CNS challenges.

Based on the provided data, AXSMs stock is trading at 106.27, above its 20-day SMA (104.69) but below 50-day (117.28) and 200-day (98.39) SMAs, suggesting a neutral trend with potential resistance at 117.28. The ATR of 4.97 indicates moderate volatility.

With a market cap of $5.05 billion and P/S of 13.09, AXSM reflects high growth expectations. The 3-month forecast predicts price movements influenced by clinical data, particularly from AXS-05 and AXS-12 trials. Support is anticipated near the 200-day SMA (98.39), with resistance at recent highs (117.28). The stocks performance will likely hinge on pipeline developments and market sentiment towards CNS therapies.